Vaxcyte (NASDAQ:PCVX) EVP Jim Wassil Sells 2,250 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) EVP Jim Wassil sold 2,250 shares of the business’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $60.90, for a total value of $137,025.00. Following the completion of the transaction, the executive vice president owned 145,435 shares in the company, valued at $8,856,991.50. This trade represents a 1.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jim Wassil also recently made the following trade(s):

• On Monday, October 5th, Jim Wassil sold 18,000 shares of Vaxcyte stock. The stock was sold at an average price of $86.74, for a total value of $1,561,320.00.
• On Thursday, October 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $56.67, for a total value of $127,507.50.
• On Wednesday, September 9th, Jim Wassil sold 1,334 shares of Vaxcyte stock. The shares were sold at an average price of $59.52, for a total value of $79,399.68.
• On Friday, September 4th, Jim Wassil sold 1,381 shares of Vaxcyte stock. The shares were sold at an average price of $61.16, for a total value of $84,461.96.
• On Tuesday, September 1st, Jim Wassil sold 3,477 shares of Vaxcyte stock. The stock was sold at an average price of $61.07, for a total value of $212,340.39.

Vaxcyte Price Performance

PCVX traded up $4.87 during midday trading on Wednesday, hitting $65.68. 2,257,729 shares of the company’s stock traded hands, compared to its average volume of 1,640,595. The company has a market cap of $9.77 billion, a PE ratio of -8.61 and a beta of 1.31. The stock’s fifty day simple moving average is $61.55 and its 200-day simple moving average is $57.07. Vaxcyte, Inc. has a one year low of $39.87 and a one year high of $90.75.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Wednesday, November 4th. The company reported ($1.99) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.11) by $0.12. On average, research analysts expect that Vaxcyte, Inc. will post -7.47 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Zacks Research raised shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Wall Street Zen raised shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Cantor Fitzgerald restated an “overweight” rating and set a $120.00 target price on shares of Vaxcyte in a report on Monday, October 12th. Bank of America reduced their price target on Vaxcyte from $133.00 to $130.00 and set a “buy” rating for the company in a research report on Monday, September 28th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research report on Friday, October 2nd. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $110.50.

Institutional Trading of Vaxcyte

Large investors have recently modified their holdings of the company. First Light Asset Management LLC raised its holdings in Vaxcyte by 143.4% in the 2nd quarter. First Light Asset Management LLC now owns 345,157 shares of the company’s stock worth $20,064,000 after acquiring an additional 203,373 shares during the period. Bank of America Corp DE lifted its position in Vaxcyte by 73.4% during the 1st quarter. Bank of America Corp DE now owns 1,216,843 shares of the company’s stock worth $70,711,000 after acquiring an additional 515,209 shares during the last quarter. Candriam S.C.A. acquired a new position in Vaxcyte during the 1st quarter worth $18,306,000. Seven Fleet Capital Management LP lifted its position in Vaxcyte by 406.4% during the 1st quarter. Seven Fleet Capital Management LP now owns 128,450 shares of the company’s stock worth $7,464,000 after acquiring an additional 103,085 shares during the last quarter. Finally, Engineers Gate Manager LP acquired a new stake in shares of Vaxcyte in the second quarter valued at about $1,906,000. 96.78% of the stock is owned by institutional investors.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines designed to protect against serious bacterial diseases. The company is headquartered in San Carlos, California, and uses its proprietary cell-free protein synthesis and conjugation technologies to develop vaccine candidates intended to provide broad and durable immune protection.

Vaxcyte’s lead programs target pneumococcal disease, an infection caused by Streptococcus pneumoniae.